cd2-innovation-ws (Overview)

Virtual meeting via WebEx, October 8-9, 2020
This workshop will be invitational only


The Cancer Diagnostic Devices (CD2) Interagency Task Force is a collaborative effort among the National Cancer Institute, U.S. Food and Drug Administration, Health Resources and Services Administration, and Centers for Medicare & Medicaid Services focused on cancer diagnostics for near-patient use. The goal of this inaugural workshop is to drive innovation in cancer screening, surveillance, and early detection for near-patient use to address critical, unmet needs in geographically isolated, medically underserved, and otherwise vulnerable communities. The workshop will identify barriers to facilitate new opportunities for diagnostics design, development, and implementation in early cancer detection and screening. Following the workshop, a report will be developed to summarize key takeaways and recommendations for further consideration by NCI, in collaboration with other agency leaders.

Areas of Focus

  • Advancing research
    • Design, develop and validate new and existing cancer diagnostics
    • Establish feasibility and acceptability of cancer screening, surveillance, early detection strategies among both provider and patient groups in in geographically isolated, medically underserved, and otherwise vulnerable communities
  • Improving education among developers on regulatory and technical processes 
  • Creating opportunities to design, implement, and evaluate intervention strategies for the use of cancer diagnostics in populations experiencing health disparities and health inequities